Drug-Drug Interaction Studies

Definition and scope

Studies of whether concurrent or sequential drug exposures alter an outcome relative to explicitly defined alternative treatment strategies, addressing the timing and selection specific to combinations. The target population, use, and analysis remain protocol decisions; this card explains the choices and their consequences rather than approving a study.

Operational specification

Identify the object drug, interacting drug, plausible mechanism, exposure overlap, induction/offset windows, treatment alternatives, and interaction scale. Specify initiation order and time zero; a prevalent object-drug cohort with new interacting-drug initiation differs from jointly initiating both drugs. Define the comparison that separates an interaction question from the independent effect of adding another drug.

Analysis and diagnostics

Use a justified active-comparator, factorial-contrast, self-controlled, or other design matched to the mechanism and data. Assess confounding by indication for both drugs, treatment changes prompted by interaction warnings, depletion of susceptibles, surveillance, and time-varying exposure. Report joint exposure risks and scale-specific interaction measures with uncertainty; pharmacokinetic interaction does not by itself establish clinical harm.

When NOT to use and common errors

Do not define baseline combination use from a future second prescription, compare any co-use with all non-use without assessing why the drugs were prescribed, assume additive and multiplicative interactions are interchangeable, or infer ingestion from supply overlap alone.

Worked example and implementation boundary

In a synthetic four-group example, risks are 0.20 for both drugs, 0.10 for A alone, 0.08 for B alone, and 0.05 for neither. Calculate the additive interaction contrast. The descriptive additive interaction contrast is 0.07, or seven percentage points. A causal interaction interpretation requires an identified four-strategy comparison. The code performs that explicitly stated calculation with synthetic inputs. It is not a complete fitted analysis and does not demonstrate the identification assumptions, estimate sampling uncertainty, or certify application in another population.

Data-source and reporting requirements

Preserve the provenance, dates, units, and observation rule for each input. Claims capture services and transactions under observable benefits; absence of a record is not proof that an event or resource use did not occur. EHR and registry measurements depend on the collection process and may miss care outside the system. Linked sources add reconciliation and selection questions. Primary collection can improve a missing domain but still requires valid measurement and follow-up. Report which of these limitations affects the stated use, which evidence supports the chosen inputs, and what remains uncertain.

Worked example

Scenario

In a synthetic four-group example, risks are 0.20 for both drugs, 0.10 for A alone, 0.08 for B alone, and 0.05 for neither. Calculate the additive interaction contrast.

Dataset

Synthetic inputs with units defined in the scenario; no patient data.

Steps

Result

The descriptive additive interaction contrast is 0.07, or seven percentage points. A causal interaction interpretation requires an identified four-strategy comparison.

Trade-offs

Code example

risk_ab = 0.2
risk_a = 0.1
risk_b = 0.08
risk_neither = 0.05
result = risk_ab-risk_a-risk_b+risk_neither
assert abs(result - 0.07) < 1e-9
print(result)

risk_ab <- 0.2
risk_a <- 0.1
risk_b <- 0.08
risk_neither <- 0.05
result <- risk_ab-risk_a-risk_b+risk_neither
stopifnot(abs(result - 0.07) < 1e-9)
print(result)

data worked_example;
  risk_ab = 0.2;
  risk_a = 0.1;
  risk_b = 0.08;
  risk_neither = 0.05;
  result = risk_ab-risk_a-risk_b+risk_neither;
  put result=;
run;

Citations

1. [1]Chen C, et al. Evaluation of Drug–Drug Interactions in Pharmacoepidemiologic Research. Pharmacoepidemiology and Drug Safety. 2025.
2. [2]VanderWeele TJ, et al. A Tutorial on Interaction. Epidemiologic Methods. 2014.